Christopher Contag retweetet

Preliminary data for CRX100 indicate that this treatment could alter the tumor microenvironment to improve responses to other therapies in patients with recurrent, platinum-resistant ovarian cancer. @StanfordMed #ovca #oncology onclive.com/view/early-dat…

English













